Increased bactericidal activity but dose-limiting intolerability at 50 mg·kg-1 rifampicin.
Lindsey H M Te BrakeVeronique de JagerKim NarunskyNaadira VankerElin M SvenssonPatrick Peter John PhillipsStephen H GillespieNorbert HeinrichMichael HoelscherRodney DawsonAndreas H DiaconRob E AarnoutseMartin J Boereenull nullPublished in: The European respiratory journal (2021)
Although associated with an increased bactericidal effect, the 50 mg·kg-1 dose was not well tolerated. Rifampicin at 40 mg·kg-1 was well tolerated and therefore selected for evaluation in a phase IIc treatment-shortening trial.